首页> 外文期刊>Therapeutic Drug Monitoring >Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993-2007.
【24h】

Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993-2007.

机译:血浆氯氮平,去甲氯氮平和氯氮平:去氯氮平的比例与处方剂量和其他因素的关系:治疗药物监测服务的数据,1993-2007年。

获取原文
获取原文并翻译 | 示例
       

摘要

Therapeutic drug monitoring of plasma clozapine and of its principal plasma metabolite N-desmethylclozapine (norclozapine) (predose or "trough" sample) can help in monitoring adherence, in dose adjustment, and in minimizing the risk of toxicity. To obtain data to assist in the interpretation of analytical results, the results from a clozapine therapeutic drug monitoring service, 1993-2007, have been audited. There were 104,127 samples from 26,796 patients [18,750 (70%) men aged at time of first sample (median, range) 34 (10-89) years, and 7763 (30%) female aged 38 (12-90) years]. Clozapine was not detected (plasma concentration <0.01 mg/L) in 1.5% of samples (prescribed clozapine dose up to 900 mg/d). Plasma clozapine was either below 0.35 mg/L or greater than 0.60 mg/L in 42.5% and 28.4% of samples, respectively; in 0.4% samples plasma clozapine was 2.0 mg/L or more. Although plasma clozapine was broadly related to prescribed dose, there was much variation: 1.2% of samples had plasma clozapine >1.0 mg/L at prescribed clozapine doses up to 150 mg/d (76.2% < 0.35 mg/L), whereas 23.3% of samples had plasma clozapine < 0.35 mg/L at doses of 850 mg/d and over (18.0% > 1.0 mg/L). The highest plasma clozapine and norclozapine concentrations encountered were 4.95 and 2.45 mg/L, respectively. Although the median plasma clozapine:norclozapine ratio was 1.25 at plasma clozapine concentrations < 0.35 mg/L, the median ratio was 2.08 at plasma clozapine concentrations > 1.0 mg/L. Data (median, 10th-90th percentile) for both clozapine and norclozapine by prescribed clozapine dose band are useful in assessing partial adherence. Analysis of the plasma clozapine:norclozapine ratio by clozapine concentration provides clear evidence that clozapine N-demethylation becomes saturated at higher plasma clozapine concentrations and adds urgency to the requirement for dose adjustment should smoking habit change. A clozapine:norclozapine ratio greater then 2 suggests either a nontrough sample, or that clozapine N-demethylation has become saturated.
机译:血浆氯氮平及其主要血浆代谢物N-去甲基氯氮平(去甲氯氮平)(给药前或“低谷”样品)的治疗药物监测可有助于监测依从性,剂量调整并最大程度地降低毒性风险。为了获得有助于解释分析结果的数据,已经审核了氯氮平治疗药物监测服务(1993-2007年)的结果。共有来自26,796名患者的104,127个样本[第一次抽样时的中位年龄为18,750(70%)男性(中位,范围)为34(10-89)岁,年龄为38(12-90)岁的女性为7763(30%)岁。在1.5%的样品(规定的氯氮平剂量最高为900 mg / d)中未检测到氯氮平(血浆浓度<0.01 mg / L)。血浆氯氮平在42.5%和28.4%的样品中分别低于0.35 mg / L或大于0.60 mg / L;在0.4%的样品中,血浆氯氮平为2.0 mg / L或更高。尽管血浆氯氮平与处方剂量广泛相关,但仍存在很大差异:1.2%的样本在血浆氯氮平的最高剂量为150 mg / d时血浆氯氮平> 1.0 mg / L(76.2%<0.35 mg / L),而23.3% 850毫克/天及以上剂量的血浆氯氮平浓度<0.35毫克/升(18.0%> 1.0毫克/升)。遇到的最高血浆氯氮平和去氯氮平浓度分别为4.95和2.45 mg / L。尽管血浆氯氮平浓度<0.35 mg / L时血浆氯氮平:去氯氮平中位数比为1.25,而血浆氯氮平浓度> 1.0 mg / L时中位数比值为2.08。规定的氯氮平剂量范围的氯氮平和去甲氯氮平的数据(中位数为百分之十至百分之九十)可用于评估部分依从性。通过氯氮平浓度分析血浆氯氮平:去氯氮平比率提供了明确的证据,表明氯氮平N-去甲基化在较高的血浆氯氮平浓度下会饱和,并且如果吸烟习惯发生变化,则迫切需要调整剂量。大于2的氯氮平:去氯氮平比值高可能说明氯氮平的N-去甲基化程度已达到饱和。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号